Prostamax
Summary
Prostamax is a Khavinson-class tetrapeptide (Lys-Glu-Asp-Pro, KEDP) positioned as a prostate bioregulator. The only prostate-specific evidence is one organotypic culture study showing stimulated growth of rat prostate explants; the rest of the indexed record is chromatin biophysics in lymphocytes from elderly donors. No human trial, in vivo prostate study, or pharmacokinetic study of the synthetic peptide has been published.
Also known as: KEDP, Lys-Glu-Asp-Pro
Key Findings at a Glance
- • Prostamax (Lys-Glu-Asp-Pro) is a synthetic tetrapeptide positioned in the Khavinson literature as a prostate-directed bioregulator.
- • The only prostate-specific evidence is an organotypic culture study in which 0.05 ng/ml Prostamax stimulated rat prostate gland explants; no in vivo prostate study of the synthetic peptide is indexed in PubMed.
- • In lymphocytes from donors aged 75 to 86, Prostamax decondensed age-condensed chromatin and altered sister chromatid exchange frequency and nucleolar organizer activity.
- • Clinical papers about prostate bioregulator therapy concern bovine prostate extract drugs such as Vitaprost, which are chemically different from the synthetic KEDP tetrapeptide.
Prostamax Overview & Molecular Profile
Prostamax (Lys-Glu-Asp-Pro, coded KEDP) is a synthetic tetrapeptide described in the Khavinson bioregulator literature as prostate-directed. The prostate-specific evidence is a single organotypic tissue culture study in which 0.05 ng/ml Prostamax stimulated growth of prostatic gland explants from both young and aged rats, alongside parallel tissue-specific effects of sibling peptides on heart, lung, and pancreas explants. The remainder of the indexed record is chromatin biophysics: microcalorimetry and cytogenetic studies in lymphocytes from donors aged 75 to 86 describe decondensation of age-condensed heterochromatin, increased sister chromatid exchange frequency, and altered nucleolar organizer activity after peptide exposure. Prostamax is frequently confused online with bovine prostate extract drugs such as Vitaprost and Samprost, which are chemically different products with their own clinical literature. No in vivo prostate study, no human trial, and no pharmacokinetic study of the synthetic peptide has been published.
Mechanism of Action: Gene Expression & Epigenetic Regulation
Within the Khavinson framework, Prostamax is proposed to act through direct interaction with chromatin and DNA rather than through a membrane receptor. Microcalorimetry showed the peptide redistributes heat among chromatin denaturation transitions and shifts them to lower temperatures in human lymphocytes, interpreted as partial relaxation of the 30-nanometer chromatin fiber into the 10-nanometer filament. Cytogenetic work from the collaborating Tbilisi group describes deheterochromatinization of aged chromatin with release of repressed genes. An independent Russian Academy of Sciences group provided the only evidence from outside the originating network: short peptides including KEDP altered DNA melting temperature and double-helix stability, with docking simulations placing glutamate contacts in the major groove and showing disrupted hydrogen bonds between strands. No receptor target has been identified, and the prostate specificity claimed for the peptide rests on one organotypic culture experiment.
Prostamax Pharmacokinetics: Only a Culture Concentration Is Known
No pharmacokinetic study exists for Prostamax in any species. The single quantitative exposure figure in the indexed literature is an in vitro concentration: 0.05 ng/ml stimulated prostate gland explants in organotypic culture. Every other aspect of absorption, distribution, metabolism, and excretion is unstudied.
The Only Quantitative Data Points
- • In organotypic tissue culture, Prostamax at 0.05 ng/ml stimulated prostatic gland explants from both young and aged rats; this is a cell-culture concentration, not a measured plasma level (PMID 17152728).
- • Lymphocyte chromatin studies used ex vivo exposure of cells from donors aged 75 to 86, again without any in vivo concentration reference (PMID 23221144).
- • No half-life, bioavailability, clearance, or tissue-distribution measurement has been published for the peptide.
Why Extrapolation Is Not Possible
- • Dosing schedules circulating in community sources are extrapolated from unrelated Khavinson peptides and from prostate extract drugs such as Vitaprost, which is a chemically different product with its own clinical literature (PMID 34251104).
- • Biophysical work indicates direct peptide-DNA interaction for KEDP, which would make conventional exposure metrics poor predictors of effect even if they were measured (PMID 25841380).
- • Until a formal pharmacokinetic study exists, any stated human dose for Prostamax is unsupported by the indexed literature.
Research-Observed Effects
Prostate Tissue Trophic Activity
Preliminary ResearchThe only prostate-specific experimental evidence for Prostamax is an organotypic tissue culture study in which the peptide at 0.05 ng/ml stimulated growth of prostatic gland explants from both young (3-week-old) and aged (18-month-old) rats. In the same experiment, cardiogen, bronchogen, and pancragen showed parallel tissue-specific stimulation of heart, lung, and pancreas explants respectively, which the authors present as evidence for the tissue-targeting principle of the bioregulator family. The authors propose such peptides for stimulation of reparative processes in aging tissues. No in vivo prostate study of the synthetic KEDP tetrapeptide, in any species, is indexed in PubMed.
Chromatin Deheterochromatinization in Aged Cells
Preliminary ResearchIn lymphocytes from donors aged 75 to 86 years, Prostamax changed chromosomal parameters in culture: sister chromatid exchange frequency rose from 5.9 to 12.0 per cell, the frequency of Ag-positive nucleolar organizer regions rose from 0.95 to 2.5 per cell, and large pericentromeric heterochromatin segments on chromosomes 1 and 9 were reduced. The authors interpret the pattern as decondensation of age-condensed chromatin releasing repressed genes, and they propose this modifying effect on chromatin as the basis of the peptide's protective action. The work comes from the collaborating Tbilisi group and measures cytogenetic endpoints rather than functional outcomes.
Heterochromatin Thermal Stability Effects
Preliminary ResearchMicrocalorimetric analysis of human lymphocytes showed that Prostamax redistributes heat among chromatin denaturation endotherms and shifts both major transitions to lower temperatures, a pattern the authors connect to partial relaxation of the 30-nanometer chromatin fiber into the 10-nanometer filament and to small structural changes in nucleosomal organization. A follow-up study examined combined exposure with copper and cadmium ions, finding that copper ions caused additional condensation of heterochromatin while cadmium caused decondensation and partial denaturation. These biophysical studies characterize how the peptide alters chromatin structure in situ, without functional or clinical endpoints.
Direct DNA Interaction
Preliminary ResearchAn independent Russian Academy of Sciences group studying how amino acids, peptides, and proteins interact with DNA found that short peptides including KEDP alter DNA melting temperature and the stability of the double helix. Measurement of melting temperatures confirmed that acidic residues weaken hydrogen bonding between strands while basic residues strengthen it, and docking simulations explored a model in which glutamate binds double-stranded DNA in the major groove and disrupts three hydrogen bonds. This is the only Prostamax-related evidence from outside the Khavinson and Tbilisi network, and it supports the physical plausibility of direct peptide-DNA interaction as a class mechanism.
Safety & Tolerability
No human safety data exist for Prostamax: the synthetic KEDP tetrapeptide has no published clinical trial, pharmacokinetic study, or toxicology assessment. Published work is limited to chromatin biophysics in lymphocytes from elderly donors and one organotypic rat prostate culture study reporting stimulated proliferative activity. That same trophic activity is why a theoretical caution exists around any use in the presence of prostate malignancy.
Human data: No human interventional or observational studies of synthetic Prostamax (KEDP) have been published. Human-related data are ex vivo lymphocyte chromatin studies. Clinical papers sometimes associated with the name online concern bovine prostate extract drugs such as Vitaprost, which are different products.
Regulatory status: Not approved for human use by the FDA, EMA, or any other major regulatory agency; no verified pharmaceutical registration. Sold as a research compound.
- PubMed 17152728
Prostamax at 0.05 ng/ml stimulated growth of rat prostate gland explants in organotypic culture; a peptide reported to stimulate prostate tissue proliferation raises a theoretical concern in the context of undiagnosed or active prostate malignancy, and this has never been clinically evaluated.
Theoretical - PubMed 23221144
Lymphocyte chromatin studies from donors aged 75 to 86 describe deheterochromatinization and an increase in sister chromatid exchange frequency from 5.9 to 12.0 per cell after Prostamax exposure; sister chromatid exchange is a cytogenetic change whose long-term significance at these exposure conditions the authors do not address.
In-vitro - PubMed 15612551
Microcalorimetric work showed Prostamax alters heterochromatin thermal stability in human lymphocytes in situ; these biophysical chromatin effects have no accompanying safety characterization.
In-vitro
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Prostamax is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
The only concentration documented in the indexed literature is 0.05 ng/ml in organotypic rat prostate tissue culture. No animal in vivo dose-response study and no human dosing protocol has been published for the synthetic tetrapeptide; community dosing schedules are extrapolations from unrelated products.
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
Zakutskii AN, Chalisova NI, Ryzhak GA, et al.
Advances in Gerontology (2006)
This organotypic culture study is the only prostate-specific experiment on Prostamax indexed in PubMed. The synthetic peptides cardiogen, bronchogen, prostamax, and pancragen were tested on explants of heart, lungs, prostatic gland, and pancreas from young (3-week-old) and aged (18-month-old) rats. Each peptide at an effective concentration of 0.05 ng/ml showed a stimulating effect in the appropriate tissue culture compared with control explants in all age groups. The authors propose these bioregulatory peptides for stimulation of reparative processes in the corresponding tissues during aging. The study establishes tissue culture tropism, not in vivo efficacy, and no prostate in vivo follow-up is indexed.
Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)
Dzhokhadze TA, Buadze TZh, Gaiozishvili MN, et al.
Georgian Medical News (2012)
This cytogenetic study examined chromosomes in cells from old individuals (75 to 86 years) exposed to Prostamax, measuring sister chromatid exchange frequency, Ag-positive nucleolar organizer regions, and structural pericentromeric heterochromatin. Prostamax increased sister chromatid exchange frequency to 12.0 per cell versus 5.9 in intact cells, increased Ag-positive nucleolar organizer regions to 2.5 per cell versus 0.95, and reduced large pericentromeric heterochromatin segments on chromosomes 1 and 9. The authors interpret the results as deheterochromatinization of aged chromatin releasing repressed genes, and propose that this modifying effect on chromatin underlies the peptide's protective action.
The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ
Meskhi T, Khachidze D, Barbakadze Sh, et al.
Biofizika (2004)
This microcalorimetric study characterized the thermal denaturation of chromatin in human lymphocytes and its modification by Prostamax. Lymphocyte chromatin showed two denaturation stages, and the peptide caused a redistribution of heat among endotherms with a shift of both major transitions to lower temperatures by 2.9 and 1.0 degrees Celsius respectively. The authors propose that the heat redistribution reflects partial relaxation of the 30-nanometer chromatin fiber into the 10-nanometer filament, with small structural changes in nucleosomal organization. The work provides biophysical evidence that Prostamax alters chromatin structure in situ in human cells.
Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax
Kiladze M, Gorgoshidze M, Monaselidze J, et al.
Georgian Medical News (2009)
This follow-up biophysical study examined the separate and combined influence of Prostamax and copper (II) and cadmium (II) ions on chromatin structure in blood lymphocyte cultures from aging people, using thermal denaturation characteristics as the readout. At the low concentrations used, the metal ions did not influence the temperature stability of membrane, nuclear, or cytoplasmic proteins, but copper ions caused additional condensation of heterochromatin while cadmium ions caused decondensation and partial denaturation. The study extends the microcalorimetric characterization of Prostamax's chromatin effects into a heavy-metal co-exposure context.
The interaction of amino acids, peptides, and proteins with DNA
Solovyev AY, Tarnovskaya SI, Chernova IA, et al.
International Journal of Biological Macromolecules (2015)
This study from the Institute of Macromolecular Compounds of the Russian Academy of Sciences, a group outside the Khavinson and Tbilisi network, examined how charged amino acids and short peptides interact with double-stranded DNA. Melting temperature measurements confirmed that acidic residues (Glu, Asp) weaken hydrogen bonding between strands while basic residues (Arg, Lys) strengthen it, with a rank correlation between amino acid isoelectric points and the observed temperature changes. Short peptides containing mixed acidic and basic residues, including KE, AEDG, and KEDP, also affected melting temperature and double-helix stability, and docking simulations modeled glutamate binding in the major groove with disruption of three hydrogen bonds. The work provides independent physical-chemical support for direct peptide-DNA interaction.
Frequently Asked Questions
What is Prostamax?
Prostamax is a synthetic tetrapeptide, Lys-Glu-Asp-Pro (KEDP), described in the Khavinson bioregulator literature as a prostate-directed peptide. Published research covers organotypic rat prostate culture and chromatin biophysics in lymphocytes from elderly donors. It should not be confused with bovine prostate extract drugs such as Vitaprost or Samprost, which are different products with their own clinical literature. It is not approved for human use anywhere.
What prostate research exists on Prostamax?
The only prostate-specific experiment indexed in PubMed is an organotypic tissue culture study in which Prostamax at 0.05 ng/ml stimulated growth of rat prostate gland explants from young and aged animals (PMID: 17152728). No in vivo animal prostate study and no human study of the synthetic KEDP tetrapeptide is indexed. Dosing schedules circulating online extrapolate from extract drugs and unrelated peptides, not from KEDP data.
Is Prostamax the same as Vitaprost or Samprost?
No. Vitaprost is a bovine prostate extract drug studied in a randomized human trial for benign prostatic hyperplasia with chronic prostatitis (PMID: 34251104), and Samprost is a similar extract drug studied in a rat chronic aseptic prostate inflammation model (PMID: 22803042). Prostamax is a single defined synthetic tetrapeptide. The extract trial results cannot be attributed to Prostamax, and community sources that cite the extract literature as Prostamax evidence are conflating different products.
Has Prostamax been studied in humans?
The synthetic peptide has no published human study. Human-related data are ex vivo chromatin experiments on lymphocytes from donors aged 75 to 86, where Prostamax produced deheterochromatinization and changed sister chromatid exchange frequency and nucleolar organizer activity (PMID: 23221144). These are cytogenetic measurements in cultured cells, not clinical outcomes.
Is Prostamax safe?
No safety data exist: no toxicology study, no human trial, and no pharmacokinetic characterization. The organotypic culture finding of stimulated prostate tissue proliferation is the basis for a theoretical caution about use with undiagnosed or active prostate malignancy, since stimulating prostate cell growth in that setting could be harmful; this concern has never been clinically evaluated (PMID: 17152728). Prostamax is an unapproved research compound.
Related Peptides
View allTestagen
Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly) of the Khavinson bioregulator class, studied in hypophysectomized bird models for pituitary-thyroid axis effects. No human trials exist.
Livagen
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed as the liver-directed member of the Khavinson bioregulator family, studied in hepatocyte culture, digestive enzyme, and chromatin research.
Cortagen
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) built from amino acid analysis of the bovine brain cortex preparation Cortexin, studied in nerve regeneration and cerebral ischemia models.
Vilon
Vilon is a synthetic dipeptide (Lys-Glu, KE) identified as an active constituent of the thymus polypeptide complex Thymalin, studied for T-cell differentiation and cytokine modulation.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.